[{"id":"116e49b9-25ff-4c8b-8c1c-a81e2d73d438","acronym":"","url":"https://clinicaltrials.gov/study/NCT05678270","created_at":"2023-01-10T14:58:55.552Z","updated_at":"2024-07-02T16:35:20.602Z","phase":"Phase 2","brief_title":"A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma","source_id_and_acronym":"NCT05678270","lead_sponsor":"Beijing InnoCare Pharma Tech Co., Ltd.","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 fusion","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gunagratinib (ICP-192)"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 11/15/2022","start_date":" 11/15/2022","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-02-07"},{"id":"646bc9ea-cd2c-4652-ba70-0a8a88e2cb29","acronym":"","url":"https://clinicaltrials.gov/study/NCT04565275","created_at":"2021-01-18T21:48:35.840Z","updated_at":"2024-07-02T16:35:53.319Z","phase":"Phase 1/2","brief_title":"A Study of ICP-192 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT04565275","lead_sponsor":"Beijing InnoCare Pharma Tech Co., Ltd.","biomarkers":" FGFR","pipe":"","alterations":" ","tags":["FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gunagratinib (ICP-192)"],"overall_status":"Recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 02/01/2021","start_date":" 02/01/2021","primary_txt":" Primary completion: 11/30/2023","primary_completion_date":" 11/30/2023","study_txt":" Completion: 04/15/2024","study_completion_date":" 04/15/2024","last_update_posted":"2023-03-14"},{"id":"059be10f-2a45-47c2-978f-ca17df6ee6cf","acronym":"ICP-CL-00301","url":"https://clinicaltrials.gov/study/NCT03758664","created_at":"2021-01-18T18:28:29.537Z","updated_at":"2024-07-02T16:36:07.705Z","phase":"Phase 1/2","brief_title":"Clinical Study of ICP-192 in Solid Tumors Patients","source_id_and_acronym":"NCT03758664 - ICP-CL-00301","lead_sponsor":"Beijing InnoCare Pharma Tech Co., Ltd.","biomarkers":" FGFR2 • FGFR","pipe":" | ","alterations":" FGFR2 fusion • FGFR2 translocation","tags":["FGFR2 • FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 fusion • FGFR2 translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gunagratinib (ICP-192)"],"overall_status":"Recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 12/19/2018","start_date":" 12/19/2018","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2022-07-06"}]